{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T08:32:31Z","timestamp":1793521951825,"version":"4.5.0"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T00:00:00Z","timestamp":1556668800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Bull Math Biol"],"published-print":{"date-parts":[[2019,7]]},"DOI":"10.1007\/s11538-019-00608-x","type":"journal-article","created":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T16:04:00Z","timestamp":1556726640000},"page":"2345-2395","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["To Cure or Not to Cure: Consequences of Immunological Interactions in CML Treatment"],"prefix":"10.1007","volume":"81","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3634-0061","authenticated-orcid":false,"given":"Artur","family":"C\u00e9sar Fassoni","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingo","family":"Roeder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingmar","family":"Glauche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,5,1]]},"reference":[{"key":"608_CR1","volume-title":"Algorithms in real algebraic geometry","author":"S Basu","year":"2007","unstructured":"Basu S, Pollack R, Coste-Roy MF (2007) Algorithms in real algebraic geometry, vol 10. Springer, Berlin"},{"issue":"5","key":"608_CR2","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1007\/s11538-017-0272-7","volume":"80","author":"A Besse","year":"2018","unstructured":"Besse A, Clapp GD, Bernard S, Nicolini FE, Levy D, Lepoutre T (2018) Stability analysis of a model of interaction between the immune system and cancer cells in chronic myelogenous leukemia. Bull Math Biol 80(5):1084\u20131110","journal-title":"Bull Math Biol"},{"key":"608_CR3","doi-asserted-by":"publisher","first-page":"2851","DOI":"10.1200\/JCO.2015.66.2866","volume":"34","author":"H Bower","year":"2016","unstructured":"Bower H, Bjrkholm M, Dickman PW, Hglund M, Lambert PC, Andersson TML (2016) Life expectancy of patients with chronic myeloid leukemia approaches the life expectancy of the general population. J Clin Oncol 34:2851\u20132857. \n                    https:\/\/doi.org\/10.1200\/JCO.2015.66.2866","journal-title":"J Clin Oncol"},{"issue":"8","key":"608_CR4","doi-asserted-by":"publisher","first-page":"2688","DOI":"10.1182\/blood-2005-03-1240","volume":"106","author":"SN Catlin","year":"2005","unstructured":"Catlin SN, Guttorp P, Abkowitz JL (2005) The kinetics of clonal dominance in myeloproliferative disorders. Blood 106(8):2688\u20132692. \n                    https:\/\/doi.org\/10.1182\/blood-2005-03-1240","journal-title":"Blood"},{"issue":"Suppl 2","key":"608_CR5","doi-asserted-by":"publisher","first-page":"S107","DOI":"10.1007\/s00277-015-2325-z","volume":"94","author":"B Chereda","year":"2015","unstructured":"Chereda B, Melo JV (2015) Natural course and biology of CML. Ann Hematol 94(Suppl 2):S107\u2013S121. \n                    https:\/\/doi.org\/10.1007\/s00277-015-2325-z","journal-title":"Ann Hematol"},{"key":"608_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ddmod.2014.10.002","volume":"16","author":"G Clapp","year":"2015","unstructured":"Clapp G, Levy D (2015) A review of mathematical models for leukemia and lymphoma. Drug Discov Today Dis Models 16:1\u20136","journal-title":"Drug Discov Today Dis Models"},{"key":"608_CR7","doi-asserted-by":"publisher","first-page":"4053","DOI":"10.1158\/0008-5472.CAN-15-0611","volume":"75","author":"GD Clapp","year":"2015","unstructured":"Clapp GD, Lepoutre T, El Cheikh R, Bernard S, Ruby J, Labussire-Wallet H, Nicolini FE, Levy D (2015) Implication of the autologous immune system in BCR-ABL transcript variations in chronic myelogenous leukemia patients treated with imatinib. Cancer Res 75:4053\u20134062. \n                    https:\/\/doi.org\/10.1158\/0008-5472.CAN-15-0611","journal-title":"Cancer Res"},{"key":"608_CR8","doi-asserted-by":"publisher","first-page":"e310","DOI":"10.1016\/S2352-3026(17)30066-2","volume":"4","author":"RE Clark","year":"2017","unstructured":"Clark RE, Polydoros F, Apperley JF, Milojkovic D, Pocock C, Smith G, Byrne JL, de Lavallade H, O\u2019Brien SG, Coffey T, Foroni L, Copland M (2017) De-escalation of tyrosine kinase inhibitor dose in patients with chronic myeloid leukaemia with stable major molecular response (destiny): an interim analysis of a non-randomised, phase 2 trial. Lancet Haematol 4:e310\u2013e316. \n                    https:\/\/doi.org\/10.1016\/S2352-3026(17)30066-2","journal-title":"Lancet Haematol"},{"issue":"1","key":"608_CR9","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.jtbi.2005.02.015","volume":"236","author":"R DeConde","year":"2005","unstructured":"DeConde R, Kim PS, Levy D, Lee PP (2005) Post-transplantation dynamics of the immune response to chronic myelogenous leukemia. J Theor Biol 236(1):39\u201359","journal-title":"J Theor Biol"},{"issue":"8","key":"608_CR10","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1200\/JCO.2003.11.143","volume":"21","author":"MW Deininger","year":"2003","unstructured":"Deininger MW, Obrien SG, Ford JM, Druker BJ (2003) Practical management of patients with chronic myeloid leukemia receiving imatinib. J Clin Oncol 21(8):1637\u20131647","journal-title":"J Clin Oncol"},{"key":"608_CR11","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1177\/1947601910371122","volume":"1","author":"D Dingli","year":"2010","unstructured":"Dingli D, Traulsen A, Lenaerts T, Pacheco JM (2010) Evolutionary dynamics of chronic myeloid leukemia. Genes Cancer 1:309\u2013315. \n                    https:\/\/doi.org\/10.1177\/1947601910371122","journal-title":"Genes Cancer"},{"key":"608_CR12","doi-asserted-by":"publisher","first-page":"2408","DOI":"10.1056\/NEJMoa062867","volume":"355","author":"BJ Druker","year":"2006","unstructured":"Druker BJ, Guilhot F, O\u2019Brien SG, Gathmann I, Kantarjian H, Gattermann N, Deininger MWN, Silver RT, Goldman JM, Stone RM, Cervantes F, Hochhaus A, Powell BL, Gabrilove JL, Rousselot P, Reiffers J, Cornelissen JJ, Hughes T, Agis H, Fischer T, Verhoef G, Shepherd J, Saglio G, Gratwohl A, Nielsen JL, Radich JP, Simonsson B, Taylor K, Baccarani M, So C, Letvak L, Larson RA, Investigators I (2006) Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 355:2408\u20132417. \n                    https:\/\/doi.org\/10.1056\/NEJMoa062867","journal-title":"N Engl J Med"},{"issue":"1","key":"608_CR13","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1007\/s11538-010-9526-3","volume":"73","author":"R Eftimie","year":"2011","unstructured":"Eftimie R, Bramson JL, Earn DJ (2011) Interactions between the immune system and cancer: a brief review of non-spatial mathematical models. Bull Math Biol 73(1):2\u201332","journal-title":"Bull Math Biol"},{"key":"608_CR14","doi-asserted-by":"publisher","first-page":"1825","DOI":"10.3324\/haematol.2018.194522","volume":"103","author":"AC Fassoni","year":"2018","unstructured":"Fassoni AC, Baldow C, Roeder I, Glauche I (2018) Reduced tyrosine kinase inhibitor dose is predicted to be as effective as standard dose in chronic myeloid leukemia: a simulation study based on phase III trial data. Haematologica 103:1825\u20131834. \n                    https:\/\/doi.org\/10.3324\/haematol.2018.194522","journal-title":"Haematologica"},{"key":"608_CR15","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1016\/S0140-6736(07)61165-9","volume":"370","author":"R Hehlmann","year":"2007","unstructured":"Hehlmann R, Hochhaus A, Baccarani M, LeukemiaNet E (2007) Chronic myeloid leukaemia. Lancet (London, England) 370:342\u2013350. \n                    https:\/\/doi.org\/10.1016\/S0140-6736(07)61165-9","journal-title":"Lancet (London, England)"},{"key":"608_CR16","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1056\/NEJMoa1609324","volume":"376","author":"A Hochhaus","year":"2017","unstructured":"Hochhaus A, Larson RA, Guilhot F, Radich JP, Branford S, Hughes TP, Baccarani M, Deininger MW, Cervantes F, Fujihara S, Ortmann CE, Menssen HD, Kantarjian H, O\u2019Brien SG, Druker BJ, Investigators I (2017) Long-term outcomes of imatinib treatment for chronic myeloid leukemia. N Engl J Med 376:917\u2013927. \n                    https:\/\/doi.org\/10.1056\/NEJMoa1609324","journal-title":"N Engl J Med"},{"key":"608_CR17","volume-title":"Essential haematology. Essentials","author":"A Hoffbrand","year":"2001","unstructured":"Hoffbrand A, Pettit J, Moss P (2001) Essential haematology. Essentials. Wiley, New York"},{"issue":"5","key":"608_CR18","doi-asserted-by":"publisher","first-page":"293","DOI":"10.4039\/Ent91293-5","volume":"91","author":"CS Holling","year":"1959","unstructured":"Holling CS (1959) The components of predation as revealed by a study of small-mammal predation of the European pine sawfly. Can Entomol 91(5):293\u2013320","journal-title":"Can Entomol"},{"issue":"12","key":"608_CR19","doi-asserted-by":"publisher","first-page":"1595","DOI":"10.1182\/blood-2016-09-696013","volume":"129","author":"TL Holyoake","year":"2017","unstructured":"Holyoake TL, Vetrie D (2017) The chronic myeloid leukemia stem cell: stemming the tide of persistence. Blood 129(12):1595\u20131606","journal-title":"Blood"},{"key":"608_CR20","doi-asserted-by":"publisher","first-page":"469","DOI":"10.3389\/fimmu.2017.00469","volume":"8","author":"A Hughes","year":"2017","unstructured":"Hughes A, Yong AS (2017) Immune effector recovery in chronic myeloid leukemia and treatment-free remission. Front Immunol 8:469","journal-title":"Front Immunol"},{"key":"608_CR21","doi-asserted-by":"publisher","first-page":"1166","DOI":"10.1182\/blood-2016-10-745992","volume":"129","author":"A Hughes","year":"2017","unstructured":"Hughes A, Clarson J, Tang C, Vidovic L, White DL, Hughes TP, Yong ASM (2017) CML patients with deep molecular responses to TKI have restored immune effectors and decreased PD-1 and immune suppressors. Blood 129:1166\u20131176. \n                    https:\/\/doi.org\/10.1182\/blood-2016-10-745992","journal-title":"Blood"},{"key":"608_CR22","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.1038\/leu.2016.360","volume":"31","author":"M Ilander","year":"2017","unstructured":"Ilander M, Olsson-Strmberg U, Schlums H, Guilhot J, Brck O, Lhteenmki H, Kasanen T, Koskenvesa P, Sderlund S, Hglund M, Markevrn B, Sjlander A, Lotfi K, Dreimane A, Lbking A, Holm E, Bjreman M, Lehmann S, Stenke L, Ohm L, Gedde-Dahl T, Majeed W, Ehrencrona H, Koskela S, Saussele S, Mahon FX, Porkka K, Hjorth-Hansen H, Bryceson YT, Richter J, Mustjoki S (2017) Increased proportion of mature NK cells is associated with successful imatinib discontinuation in chronic myeloid leukemia. Leukemia 31:1108\u20131116. \n                    https:\/\/doi.org\/10.1038\/leu.2016.360","journal-title":"Leukemia"},{"key":"608_CR23","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1002\/ajh.24275","volume":"91","author":"E Jabbour","year":"2016","unstructured":"Jabbour E, Kantarjian H (2016) Chronic myeloid leukemia: 2016 update on diagnosis, therapy, and monitoring. Am J Hematol 91:252\u2013265. \n                    https:\/\/doi.org\/10.1002\/ajh.24275","journal-title":"Am J Hematol"},{"key":"608_CR24","unstructured":"Kennedy J (2001) Some polynomial theorems. \n                    https:\/\/monks.scranton.edu\/files\/courses\/ProblemSolving\/POLYTHEOREMS.pdf\n                    \n                   Online. Accessed 6 Dec 2018"},{"key":"608_CR25","doi-asserted-by":"publisher","first-page":"e1000095","DOI":"10.1371\/journal.pcbi.1000095","volume":"4","author":"PS Kim","year":"2008","unstructured":"Kim PS, Lee PP, Levy D (2008) Dynamics and potential impact of the immune response to chronic myelogenous leukemia. PLoS Comput Biol 4:e1000095. \n                    https:\/\/doi.org\/10.1371\/journal.pcbi.1000095","journal-title":"PLoS Comput Biol"},{"key":"608_CR26","doi-asserted-by":"publisher","first-page":"4904","DOI":"10.1158\/0008-5472.CAN-08-1959","volume":"69","author":"NL Komarova","year":"2009","unstructured":"Komarova NL, Wodarz D (2009) Combination therapies against chronic myeloid leukemia: short-term versus long-term strategies. Cancer Res 69:4904\u20134910. \n                    https:\/\/doi.org\/10.1158\/0008-5472.CAN-08-1959","journal-title":"Cancer Res"},{"issue":"1","key":"608_CR27","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1111\/cas.13430","volume":"109","author":"T Kumagai","year":"2018","unstructured":"Kumagai T, Nakaseko C, Nishiwaki K, Yoshida C, Ohashi K, Takezako N, Takano H, Kouzai Y, Murase T, Matsue K et al (2018) Dasatinib cessation after deep molecular response exceeding 2 years and natural killer cell transition during dasatinib consolidation. Cancer Sci 109(1):182\u2013192","journal-title":"Cancer Sci"},{"issue":"2","key":"608_CR28","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1007\/BF02460644","volume":"56","author":"VA Kuznetsov","year":"1994","unstructured":"Kuznetsov VA, Makalkin IA, Taylor MA, Perelson AS (1994) Nonlinear dynamics of immunogenic tumors: parameter estimation and global bifurcation analysis. Bull Math Biol 56(2):295\u2013321","journal-title":"Bull Math Biol"},{"issue":"1","key":"608_CR29","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1182\/blood-2003-04-1074","volume":"103","author":"P La Rosee","year":"2004","unstructured":"La Rosee P, Johnson K, Corbin AS, Stoffregen EP, Moseson EM, Willis S, Mauro MM, Melo JV, Deininger MW, Druker BJ (2004) In vitro efficacy of combined treatment depends on the underlying mechanism of resistance in imatinib-resistant Bcr-Abl-positive cell lines. Blood 103(1):208\u2013215","journal-title":"Blood"},{"key":"608_CR30","doi-asserted-by":"publisher","unstructured":"Mahon FX, Ra D, Guilhot J, Guilhot F, Huguet F, Nicolini F, Legros L, Charbonnier A, Guerci A, Varet B, Etienne G, Reiffers J, Rousselot P, des Leucmies Mylodes Chroniques IF (2010) Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre stop imatinib (STIM) trial. Lancet Oncol 11:1029\u20131035. \n                    https:\/\/doi.org\/10.1016\/S1470-2045(10)70233-3","DOI":"10.1016\/S1470-2045(10)70233-3"},{"issue":"7046","key":"608_CR31","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1038\/nature03669","volume":"435","author":"F Michor","year":"2005","unstructured":"Michor F, Hughes T, Iwasa Y, Branford S, Shah N, Sawyers C, Nowak M (2005) Dynamics of chronic myeloid leukaemia. Nature 435(7046):1267\u201370","journal-title":"Nature"},{"issue":"4","key":"608_CR32","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1016\/j.jtbi.2003.11.024","volume":"227","author":"H Moore","year":"2004","unstructured":"Moore H, Li NK (2004) A mathematical model for chronic myelogenous leukemia (CML) and T cell interaction. J Theor Biol 227(4):513\u2013523","journal-title":"J Theor Biol"},{"issue":"5","key":"608_CR33","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.1007\/s11538-010-9553-0","volume":"73","author":"D Paquin","year":"2011","unstructured":"Paquin D, Kim PS, Lee PP, Levy D (2011) Strategic treatment interruptions during imatinib treatment of chronic myelogenous leukemia. Bull Math Biol 73(5):1082\u20131100","journal-title":"Bull Math Biol"},{"key":"608_CR34","doi-asserted-by":"publisher","first-page":"1368","DOI":"10.3324\/haematol.2017.165001","volume":"102","author":"D Rea","year":"2017","unstructured":"Rea D, Henry G, Khaznadar Z, Etienne G, Guilhot F, Nicolini F, Guilhot J, Rousselot P, Huguet F, Legros L, Gardembas M, Dubruille V, Guerci-Bresler A, Charbonnier A, Maloisel F, Ianotto JC, Villemagne B, Mahon FX, Moins-Teisserenc H, Dulphy N, Toubert A (2017a) Natural killer-cell counts are associated with molecular relapse-free survival after imatinib discontinuation in chronic myeloid leukemia: the immunostim study. Haematologica 102:1368\u20131377. \n                    https:\/\/doi.org\/10.3324\/haematol.2017.165001","journal-title":"Haematologica"},{"key":"608_CR35","doi-asserted-by":"publisher","unstructured":"Rea D, Nicolini FE, Tulliez M, Guilhot F, Guilhot J, Guerci-Bresler A, Gardembas M, Coiteux V, Guillerm G, Legros L, Etienne G, Pignon JM, Villemagne B, Escoffre-Barbe M, Ianotto JC, Charbonnier A, Johnson-Ansah H, Noel MP, Rousselot P, Mahon FX, des Leucmies Mylodes Chroniques FI (2017b) Discontinuation of dasatinib or nilotinib in chronic myeloid leukemia: interim analysis of the STOP 2G-TKI study. Blood 129:846\u2013854. \n                    https:\/\/doi.org\/10.1182\/blood-2016-09-742205","DOI":"10.1182\/blood-2016-09-742205"},{"issue":"10","key":"608_CR36","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1038\/nm1487","volume":"12","author":"I Roeder","year":"2006","unstructured":"Roeder I, Horn M, Glauche I, Hochhaus A, Mueller MC, Loeffler M (2006) Dynamic modeling of imatinib-treated chronic myeloid leukemia: functional insights and clinical implications. Nat Med 12(10):1181\u20131184","journal-title":"Nat Med"},{"key":"608_CR37","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1200\/JCO.2012.48.5797","volume":"32","author":"P Rousselot","year":"2014","unstructured":"Rousselot P, Charbonnier A, Cony-Makhoul P, Agape P, Nicolini FE, Varet B, Gardembas M, Etienne G, Ra D, Roy L, Escoffre-Barbe M, Guerci-Bresler A, Tulliez M, Prost S, Spentchian M, Cayuela JM, Reiffers J, Chomel JC, Turhan A, Guilhot J, Guilhot F, Mahon FX (2014) Loss of major molecular response as a trigger for restarting tyrosine kinase inhibitor therapy in patients with chronic-phase chronic myelogenous leukemia who have stopped imatinib after durable undetectable disease. J Clin Oncol 32:424\u2013430. \n                    https:\/\/doi.org\/10.1200\/JCO.2012.48.5797","journal-title":"J Clin Oncol"},{"key":"608_CR38","doi-asserted-by":"publisher","first-page":"1638","DOI":"10.1038\/leu.2016.115","volume":"30","author":"S Saussele","year":"2016","unstructured":"Saussele S, Richter J, Hochhaus A, Mahon FX (2016) The concept of treatment-free remission in chronic myeloid leukemia. Leukemia 30:1638\u20131647. \n                    https:\/\/doi.org\/10.1038\/leu.2016.115","journal-title":"Leukemia"},{"key":"608_CR39","doi-asserted-by":"publisher","unstructured":"Saussele S, Richter J, Guilhot J, Gruber FX, Hjorth-Hansen H, Almeida A, Janssen JJWM, Mayer J, Koskenvesa P, Panayiotidis P, Olsson-Strmberg U, Martinez-Lopez J, Rousselot P, Vestergaard H, Ehrencrona H, Kairisto V, Machov Polkov K, Mller MC, Mustjoki S, Berger MG, Fabarius A, Hofmann WK, Hochhaus A, Pfirrmann M, Mahon FX, Investigators ES (2018) Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial. Lancet Oncol 19:747\u2013757. \n                    https:\/\/doi.org\/10.1016\/S1470-2045(18)30192-X","DOI":"10.1016\/S1470-2045(18)30192-X"},{"issue":"4","key":"608_CR40","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1038\/leu.2017.9","volume":"31","author":"C Sch\u00fctz","year":"2017","unstructured":"Sch\u00fctz C, Inselmann S, Sausslele S, Dietz C, M\u00fcller M, Eigendorff E, Brendel C, Metzelder S, Br\u00fcmmendorf T, Waller C et al (2017) Expression of the CTLA-4 ligand CD86 on plasmacytoid dendritic cells (PDC) predicts risk of disease recurrence after treatment discontinuation in CML. Leukemia 31(4):829","journal-title":"Leukemia"},{"issue":"2","key":"608_CR41","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1200\/JCO.2016.67.0893","volume":"35","author":"S Sopper","year":"2016","unstructured":"Sopper S, Mustjoki S, White D, Hughes T, Valent P, Burchert A, Gjertsen BT, Gastl G, Baldauf M, Trajanoski Z et al (2016) Reduced CD62l expression on T cells and increased soluble CD62l levels predict molecular response to tyrosine kinase inhibitor therapy in early chronic-phase chronic myelogenous leukemia. J Clin Oncol 35(2):175\u2013184","journal-title":"J Clin Oncol"},{"key":"608_CR42","doi-asserted-by":"publisher","first-page":"6812","DOI":"10.1158\/1078-0432.CCR-11-0396","volume":"17","author":"AM Stein","year":"2011","unstructured":"Stein AM, Bottino D, Modur V, Branford S, Kaeda J, Goldman JM, Hughes TP, Radich JP, Hochhaus A (2011) BCR-ABL transcript dynamics support the hypothesis that leukemic stem cells are reduced during imatinib treatment. Clin Cancer Res 17:6812\u20136821. \n                    https:\/\/doi.org\/10.1158\/1078-0432.CCR-11-0396","journal-title":"Clin Cancer Res"},{"key":"608_CR43","doi-asserted-by":"publisher","first-page":"1875","DOI":"10.1098\/rspb.2009.2179","volume":"277","author":"D Wodarz","year":"2010","unstructured":"Wodarz D (2010) Heterogeneity in chronic myeloid leukaemia dynamics during imatinib treatment: role of immune responses. Proc Biol Sci 277:1875\u20131880. \n                    https:\/\/doi.org\/10.1098\/rspb.2009.2179","journal-title":"Proc Biol Sci"},{"key":"608_CR44","doi-asserted-by":"publisher","first-page":"e0179700","DOI":"10.1371\/journal.pone.0179700","volume":"12","author":"C Woywod","year":"2017","unstructured":"Woywod C, Gruber FX, Engh RA, Fl T (2017) Dynamical models of mutated chronic myelogenous leukemia cells for a post-imatinib treatment scenario: response to dasatinib or nilotinib therapy. PloS ONE 12:e0179700. \n                    https:\/\/doi.org\/10.1371\/journal.pone.0179700","journal-title":"PloS ONE"},{"issue":"7","key":"608_CR45","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1038\/nrclinonc.2016.41","volume":"13","author":"L Zitvogel","year":"2016","unstructured":"Zitvogel L, Rusakiewicz S, Routy B, Ayyoub M, Kroemer G (2016) Immunological off-target effects of imatinib. Nat Rev Clin Oncol 13(7):431","journal-title":"Nat Rev Clin Oncol"}],"container-title":["Bulletin of Mathematical Biology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11538-019-00608-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11538-019-00608-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11538-019-00608-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,4,29]],"date-time":"2020-04-29T20:07:51Z","timestamp":1588190871000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11538-019-00608-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5,1]]},"references-count":45,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2019,7]]}},"alternative-id":["608"],"URL":"https:\/\/doi.org\/10.1007\/s11538-019-00608-x","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/494575","asserted-by":"object"}]},"ISSN":["0092-8240","1522-9602"],"issn-type":[{"value":"0092-8240","type":"print"},{"value":"1522-9602","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,5,1]]},"assertion":[{"value":"8 March 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 April 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 May 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}